Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB3006 in advanced malignant cancer
NCT06344351Phase 1Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Apr 2024
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TQB3006 in malignant neoplasm, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Dose limiting toxicity, Maximum tolerated dose and 1 more. Started Apr 2024; status: completed.
02
Drugs
TQB3006
03
Conditions
malignant neoplasm
Beyond the preview
Go deeper on NCT06344351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06344351.